03 August 2023 | Thursday | News
Image Source | Public Domain
“We are pleased to announce the closing of this acquisition, as the brands we are adding will strengthen, complement and expand STERIS’s product offerings within our Healthcare segment,” said Dan Carestio, President and Chief Executive Officer of STERIS. “We welcome these teams to STERIS and look forward to working together to enhance our value to our Customers.”
Lazard served as financial advisor to STERIS and Thompson Hine LLP served as legal counsel.
© 2024 Biopharma Boardroom. All Rights Reserved.